ReviewStem cell reviews and reports2026
Nanotechnology-enabled precision targeting of lung cancer stem cells: Recent developments and therapeutic implications.
Review in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains one of the leading causes of cancer-related mortality worldwide, highlighting the urgent need for more effective therapeutic strategies. Lung cancer stem cells (LCSCs) play critical roles in tumor initiation, metastasis, therapeutic resistance, and recurrence through dynamic interactions with the tumor microenvironment (TME), metabolic reprogramming, and immune evasion. Despite advances in targeted therapy and immunotherapy, conventional approaches remain insufficient for the complete elimination of LCSCs. Recent progress in nanotechnology has provided new opportunities for precision targeting of LCSCs by enhancing drug bioavailability, tumor selectivity, controlled release, and multifunctional therapeutic integration. In this review, we summarize current nanotechnology-enabled strategies targeting LCSCs, with particular emphasis on TME remodeling, metabolic regulation, and tumor immunity. Distinct from previous reviews that discuss cancer stem cells or nanomedicine separately, this review establishes an integrated framework linking LCSC niche regulation with nanotechnology-based precision therapeutics in lung cancer. We further highlight the therapeutic potential of multifunctional nanoplatforms, including nanocrystalline drugs, smart nanocarriers, and combinational nano-delivery systems, in modulating stemness-associated pathways, overcoming immune suppression, and disrupting metabolic adaptation. In addition, emerging strategies involving stimulus-responsive nanomaterials, ferroptosis induction, and engineered immunotherapeutic platforms are discussed. Finally, current challenges and future perspectives regarding tumor heterogeneity, nanocarrier biocompatibility, translational feasibility, and personalized therapeutic design are addressed. Collectively, this review provides a comprehensive perspective on nanotechnology-enabled precision targeting of LCSCs and offers insights into next-generation therapeutic strategies for lung cancer.
Indexed as
Identifiers
42501212What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.